Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PRE 
Prenetics Global Ltd (PRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: PRE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14
1 Year Target Price $14
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4.82% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 104.27M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 1 | Beta 0.17 | 52 Weeks Range 3.09 - 11.99 | Updated Date 07/4/2025 |
52 Weeks Range 3.09 - 11.99 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -115.91% | Operating Margin (TTM) -61.41% |
Management Effectiveness
Return on Assets (TTM) -14.52% | Return on Equity (TTM) -28.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 49851129 | Price to Sales(TTM) 2.51 |
Enterprise Value 49851129 | Price to Sales(TTM) 2.51 | ||
Enterprise Value to Revenue 1.2 | Enterprise Value to EBITDA 0.14 | Shares Outstanding 11453000 | Shares Floating 9154745 |
Shares Outstanding 11453000 | Shares Floating 9154745 | ||
Percent Insiders 19.88 | Percent Institutions 12.57 |
Upturn AI SWOT
Prenetics Global Ltd
Company Overview
History and Background
Prenetics Global Ltd is a genetic testing and digital health company focused on personalized healthcare. It was founded in 2013 and has grown through strategic acquisitions and expansions into various markets.
Core Business Areas
- Genetic Testing: Prenetics offers a range of genetic testing services for disease risk prediction, pharmacogenomics, and cancer screening.
- Digital Health: Provides digital health solutions, including at-home testing kits, telehealth services, and personalized wellness programs.
- Preventive Healthcare: Focuses on providing proactive healthcare solutions such as early cancer detection and personalized health plans.
Leadership and Structure
Danny Yeung is the CEO and co-founder. The company has a board of directors with experience in healthcare, technology, and finance. Organizational structure includes departments for R&D, marketing, sales, and operations.
Top Products and Market Share
Key Offerings
- CircleDNA: A comprehensive DNA test kit for ancestry, health insights, and personalized recommendations. Competitors include 23andMe and AncestryDNA. Market share is estimated at less than 5% of the global consumer genomics market. No revenue information is publicly available.
- ColoClear by Circle: Non-invasive stool DNA test for early detection of colorectal cancer. Competitors include Exact Sciences (EXAS) and Guardant Health (GH). Market share is estimated to be low. No revenue information is publicly available.
- iGenes: Pharmacogenomics test to personalize medication selection and dosage based on an individual's genetic profile. Competitors include Myriad Genetics and Invitae (NVTA). No revenue information is publicly available.
Market Dynamics
Industry Overview
The genetic testing and digital health industry is experiencing rapid growth driven by increasing awareness of personalized medicine, technological advancements, and decreasing costs of genetic sequencing.
Positioning
Prenetics aims to be a leading provider of personalized healthcare solutions by integrating genetic testing with digital health services. It competes with established players in the genetic testing market and emerging digital health companies.
Total Addressable Market (TAM)
The global genetic testing market is estimated to be over $20 billion and is growing rapidly. Prenetics' TAM includes segments like consumer genomics, cancer screening, and pharmacogenomics. Prenetics is positioned to capture a share of this market through its diverse product offerings and geographic reach.
Upturn SWOT Analysis
Strengths
- Diverse product portfolio
- Strong brand recognition in some Asian markets
- Strategic partnerships
- Focus on personalized healthcare
Weaknesses
- Limited market share in the US and Europe
- High marketing expenses
- Dependence on partnerships for distribution
- Relatively new to the market
Opportunities
- Expanding into new geographic markets
- Developing new genetic tests and digital health solutions
- Increasing adoption of personalized medicine
- Acquiring complementary businesses
Threats
- Intense competition from established players
- Changing regulations and reimbursement policies
- Data privacy and security concerns
- Economic downturn impacting consumer spending
Competitors and Market Share
Key Competitors
- 23andMe
- AncestryDNA
- EXAS
- NVTA
Competitive Landscape
Prenetics has a competitive advantage in certain Asian markets but faces intense competition from larger, more established players in the US and Europe. Prenetics needs to build a strong brand in key markets and offer more competitive pricing.
Major Acquisitions
Insighta
- Year: 2023
- Acquisition Price (USD millions): 200
- Strategic Rationale: Acquisition was for strengthening R&D capabilities and expand product portfolio.
Growth Trajectory and Initiatives
Historical Growth: Prenetics has experienced growth in revenue and customer base through strategic acquisitions and organic expansion, but specific figures are unavailable.
Future Projections: Future growth projections are dependent on factors such as market adoption of personalized medicine, regulatory approvals, and competitive landscape. Analyst estimates not available in this context.
Recent Initiatives: Recent initiatives include expanding into new markets, launching new products, and forming strategic partnerships.
Summary
Prenetics Global Ltd. is a developing player in the personalized healthcare industry with a presence primarily in Asia. They need to improve their market share in the U.S. and Europe. Key focus areas are to expand their product portfolio, and develop new genetic tests and digital health solutions. There is intense competition from well established players. Growth can be hindered by negative economic conditions or unfavorable regulatory policies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is approximate and based on available estimates. Financial data is limited due to lack of publicly available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prenetics Global Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-05-18 | Co-Founder, Chairperson & CEO Mr. Sheng Wu Yeung | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 285 | Website https://www.prenetics.com |
Full time employees 285 | Website https://www.prenetics.com | ||
Prenetics Global Limited, a consumer health company, focuses on empowering individuals to take control of their health through science-backed solutions in Hong Kong, Taiwan, the United States, and internationally. The company operates in three segments: Prevention, Diagnostics, and Consumer Health. It operates IM8 Health that sells health and wellness products; and provides fulfillment and distribution services for sports nutrition products under the Consumer Health segment. The company is also involved in the operation of CircleDNA, a consumer genetic testing brand that uses next-generation sequencing (NGS) technology to provide comprehensive insights into health, wellness, and genetic predispositions under Prevention segment.; and ACT Genomics that provides precision oncology testing services under the Diagnostics segment. In addition, it develops and commercializes multi-cancer early detection technologies. Further, the company offers a range of genomic profiling panels tailored for requirements and clinician needs. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.